The Degenerative Dementias

Textbook of Clinical Neurology: Third Edition

Volumn , Issue , 2007, Pages 699-733

  Caselli, Richard J ^a   Boeve, Bradley F ^b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873319884     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141603618-0.10033-5     Document Type: Chapter

References (192)

1. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1143-1153.
2. Crystal H, Dickson D, Fuld P, et al. Clinico-pathologic studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1988, 38:1682-1687.
3. Terry RD, Peck A, DeTeresa R Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 1981, 10:184-192.
4. Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL Alzheimer's disease: Cell-specific pathology isolates the hippocampal formation. Science 1984, 225:1168-1170.
5. Masters C, Simms G, Weinman N, et al. Amyloid plaque core protein in Alzheimer's disease and Down syndrome. Proc Natl Acad Sci USA 1985, 82:4245-4249.
6. Smith C, Anderton B The molecular pathology of Alzheimer's disease: Are we any closer to understanding the neurodegenerative process. Neuropathol Appl Neurobiol 1994, 20:322-338.
7. Hardy J, Higgins G Alzheimer's disease-The amyloid cascade hypothesis. Science 1992, 256:184-185.
8. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of P-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995, 38:643-648.
9. Vigo-Pelfrey C, Seubert P, Barbour R, et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 1995, 45:788-793.
10. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
11. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele e{open}4 with late onset familial and sporadic Alzheimer's disease. Neurology 1993, 43:1467-1472.
12. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994, 7:180-184.
13. Schmechel D, Saunders A, Strittmatter W, et al. Increased amyloid B-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993, 90:9649-9653.
14. Ma J, Yee A, Brewer H, et al. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 1994, 6501:92-94.
15. Harris FM, Brecht WJ, Xu Q, et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci USA 2003, 100:10966-10971.
16. Kounnas MZ, Moir RD, Rebeck GW, et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted B-amyloid precursor protein and mediates its degradation. Cell 1995, 82:331-340.
17. McGeer PL, Rogers J Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 1992, 42:447-449.
18. Armstrong R, Winsper S, Blair J Aluminum and Alzheimer's disease: Review of possible pathogenic mechanisms. Dementia 1996, 7:1-9.
19. Hensley K, Carney J, Mattson M, et al. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease. Proc Natl Acad Sci USA 1994, 91:3270-3274.
20. Whitehouse P, Price D, Struble R, et al. Alzheimer disease and senile dementia: Loss of neurons in basal forebrain. Science 1982, 215:1237-1239.
21. Hansen L, Masliah E, Galasko D, Terry R Plaque-only Alzheimer disease is usually Lewy body variant, and vice versa. J Neuropathol Exp Neurol 1994, 52:648-654.
22. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutation in early-onset familial Alzheimer's disease. Nature 1995, 375:754-760.
23. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995, 269:973-977.
24. Ertekin-Taner N, Graff-Radford N, Younkin LH, et al. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science 2000, 290(5500):2303-2304.
25. Wu WS, Holmans P, Wavrant-DeVrieze F, et al. Genetic studies on chromosome 12 in late-onset Alzheimer disease. JAMA 1998, 280(7):619-622.
26. Kokmen E, Beard CM, O'Brien PC, Kurland LT Epidemiology of dementia in Rochester, Minnesota. Mayo Clinic Proc 1996, 71:275-282.
27. Farrer LA, Cupples LA Estimating the probability for major gene Alzheimer disease. Am J Hum Genet 1994, 54:374-383.
28. Seshadri S, Drachman DA, Lippa CF Apolipoprotein E e{open}4 allele and the lifetime risk of Alzheimer's disease. Arch Neurol 1995, 52:1074-1079.
29. Poirer J, Davignon D, Bouthillier D, et al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993, 2:697-699.
30. Wisniewski KE, Wisniewski HM, Wen GY Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 1985, 17:278-282.
31. Petersen RC, Smith GE, Waring SE, et al. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999, 56:303-308.
32. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995, 273:1274-1278.
33. Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Neurology 2001, 56:1133-1142.
34. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment-Beyond controversies towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004, 256:240-246.
35. Rasquin SM, Lodder J, Visser PJ, Lousberg R, Verhey FR Predictive accuracy of MCI subtypes for Alzheimer's disease and vascular dementia in subjects with mild cognitive impairment: A 2-year follow-up study. Dementia Geriatr Cogn Disord 2005, 19:113-119.
36. Lopez OL, Jagust WJ, DeKosky ST, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: Part 1. Arch Neurol 2003, 60:1385-1389.
37. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early stage Alzheimer disease. Arch Neurol 2001, 58:397-405.
38. Petersen RC, Parisi JE, Dickson DW, et al. Neuropathology of amnestic mild cognitive impairment. Arch Neurol 2006, 63:665-672.
39. Morris JC The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 1993, 43:2412-2414.
40. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
41. Gearing M, Mirra SS, Hedreen JC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology 1995, 45:461-466.
42. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the e4 allele for apolipoprotein E. N Engl J Med 1996, 334:752-758.
43. Beatty WW, Salmon DP, Butters N, et al. Retrograde amnesia in patients with Alzheimer's or Huntington's disease. Neurobiol Aging 1988, 9:181-186.
44. Heindel WC, Salmon DP, Shults CW, et al. Neuropsychological evidence for multiple memory systems: A comparison of Alzheimer's, Huntington's, and Parkinson's disease patients. J Neurosci 1989, 9:582-587.
45. Fitten LJ, Perryman KM, Wilkinson CJ, et al. Alzheimer and vascular dementias and driving: A prospective road and laboratory study. JAMA 1995, 273:1360-1365.
46. Hof PR, Bouras C, Constantinidis J, Morrison JH Balint's syndrome in Alzheimer's disease: Specific disruption of the occipito-parietal visual pathway. Brain Res 1989, 493:368-375.
47. Clarfield AM The reversible dementias: Do they reverse?. Ann Intern Med 1988, 109:476-486.
48. Sink KM, Holden KF, Yaffe K Pharmacological treatment of neuropsychiatric symptoms of dementia. JAMA 2005, 293:596-608.
49. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med 2005, 353:2335-2341.
50. Dubinsky RM, Stein AC, Lyons K Risk of driving and Alzheimer's disease (an evidence based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 54:2205-2211.
51. Rizzo M, Reinach S, McGehee D, Dawson J Simulated car crashes and crash predictors in Alzheimer disease. Arch Neurol 1997, 54:545-551.
52. Drachman DA, Swearer JM Driving and Alzheimer's disease: The risk of crashes. Neurology 1993, 43:2448-2456.
53. Fox GK, Bowden SC, Bashford GM, Smith DS Alzheimer disease and driving: Prediction and assessment of driving performance. J Am Geriatr Soc 1997, 45:949-953.
54. Spangenberg KB, Wagner MT, Hendrix S, Bachman DL Firearm presence in households of patients with Alzheimer's disease and related dementias. J Am Geriatr Soc 1996, 47:1183-1186.
55. Mittelman MS, Roth DL, Coon DW, Haley WE Sustained benefit of supportive intervention for depressive symptoms in caregivers of patients with Alzheimer's disease. Am J Psychiatr 2004, 161:850-856.
56. Smith GE, Kokmen E, O'Brien PC Risk factors for nursing home placement in a population-based dementia cohort. J Am Geriatr Soc 2000, 48:519-525.
57. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003, 51:937-944.
58. Snowden DA, Kemper SJ, Mortimer JA, et al. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life: Findings from the nun study. JAMA 1996, 275:528-532.
59. Bondi MW, Salmon DP, Monsch AU, et al. Episodic memory changes are associated with the ApoE e-4 allele in nondemented older adults. Neurology 1995, 45:2203-2206.
60. McKeith IG Clinical Lewy body syndromes. Ann N Y Acad Sci 2000, 920:1-8.
61. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW Parkinson disease neuropathology: Later-developing dementia and loss of the levodopa response. Arch Neurol 2002, 59:102-112.
62. Hohl U, Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J Diagnostic accuracy of dementia with Lewy bodies. Arch Neurol 2000, 57:347-351.
63. Joachim CL, Morris JH, Selkoe DJ Clinically diagnosed Alzheimer's disease. Autopsy results in 150 cases. Ann Neurol 1988, 24:50-56.
64. Parsian A, Racette B, Goldsmith LJ, Perlmutter JS Parkinson's disease and apoliporpotein E: Possible association with dementia but not age at onset. Genomics 2002, 79:458-461.
65. Tsuang DW, Wilson RK, Lopez OL, et al. Genetic association between the ApoE4 allele and Lewy bodies in Alzheimer disease. Neurology 2005, 64:509-513.
66. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop. Neurology 1996, 47:1113-1124.
67. Katzman R, Galasko D, Saitoh T, et al. Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Brain Cogn 1995, 28:259-265.
68. Gearing M, Schneider J, Rebeck G, et al. Alzheimer's disease with and without coexisting Parkinson's disease changes: Apolipoprotein E genotype and neuropathologic correlates. Neurology 1995, 45:1985-1990.
69. Perry E, Haroutunian V, Davis K, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994, 5:747-749.
70. Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan 1988-1993. Am J Epidemiol 1995, 142:820-827.
71. Elbaz A, Bower JH, Maraganore DM, et al. Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol 2002, 55:25-31.
72. Bower JH, Maraganore DM, McDonnell SK, Rocca WA Incidence and distribution of parkinsonism in Olmsted County. Neurology 1999, 52:1214-1220.
73. Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular, and frontotemporal dementia, and hippocampal sclerosis in the state of Florida Brain Bank. Alzheimer Dis Assoc Disord 2002, 16:203-212.
74. Louis ED, Goldman JE, Powers JM, Fahn S Parkinsonian features of eight pathologically diagnosed cases of diffuse Lewy body disease. Mov Disord 1995, 10:188-194.
75. Mayeux R, Stern Y, Spanton S Heterogeneity in dementia of the Alzheimer type: Evidence of subgroups. Neurology 1985, 35:453-461.
76. Joachim CL, Morris JH, Selkoe DJ Clinically diagnosed Alzheimer's disease: Autopsy results in 150 cases. Ann Neurol 1988, 24:50-56.
77. Lippa CF, Smith TW, Saunders AM, et al. Apolipoprotein E genotype and Lewy body disease. Neurology 1995, 45:97-103.
78. Lopez OL, Wisniewski S, Hamilton RL, et al. Predictors of progression in patients with AD and Lewy bodies. Neurology 2000, 54:1774-1779.
79. Murman DL, Kuo SB, Powell MC, Colenda CC The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodies. Neurology 2003, 61:944-949.
80. McKeith IG, Dickson DW, Lowe J, et al. Dementia with Lewy bodies: Diagnosis and management: Third report of the DLB Consortium. Neurology 2005, 65:1863-1872.
81. Caselli RJ, Beach TG, Sue LI, Connor DJ, Sabbagh MN Progressive aphasia with Lewy bodies. Dementia Geriatr Cogn Disord 2002, 14:55-58.
82. Boeve BF, Silber MH, Ferman TJ, et al. REM sleep behavior disorder and degenerative dementia: An association likely reflecting Lewy body disease. Neurology 1998, 51:363-370.
83. Boeve BF, Silber MH, Ferman TJ, Lucas J, Parisi J Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 2001, 16:622-630.
84. Olson EJ, Silber MH, Boeve BF REM sleep behavior disorder: Demographic, clinical, and laboratory findings in 92 cases. Brain 2000, 123:331-339.
85. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
86. Salmon DP, Galasko D, Hansen LA, et al. Neuropsychological deficits associated with diffuse Lewy body disease. Brain Cogn 1996, 31:148-165.
87. Ferman TJ, Boeve BG, Smith GE, et al. REM sleep behavior disorder and dementia: Cognitive differences when compared with AD. Neurology 1999, 52:951-957.
88. Sugiyama H, Hainfellner J, Yoshimura M, Budka H Neocortical changes in Parkinson's disease, revisited. Clin Neuropathol 1994, 13:55-59.
89. Nauta WJH Circuitous connections linking cerebral cortex, limbic system, and corpus striatum. The Limbic System: Functional Organization and Clinical Disorders 1986, 43-54. Raven Press, New York. B.K. Doane, K.E. Livingston (Eds.).
90. Lieberman A, Dziatolowski M, Neophytides A, et al. Dementias of Huntington's and Parkinson's disease. Adv Neurol 1979, 23:273-280.
91. Aarsland D, Andersen K, Larsen J, et al. Prevalence and characteristics of dementia in Parkinson disease: An 8-year prospective study. Arch Neurol 2003, 60:387-392.
92. Yoshimura M Pathological basis for dementia in elderly patients with idiopathic Parkinson's disease. Eur Neurol 1988, 28(Suppl 1):29-35.
93. Panza F, D'Introno A, Colacicco AM, et al. Vascular risk and genetics of sporadic late-onset Alzheimer's disease. J Neural Transm 2004, 111:69-89.
94. Honig LS, Tang MX, Albert S, et al. Stroke and the risk of Alzheimer disease. Arch Neurol 2003, 60:1707-1712.
95. Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 2004, 62:1148-1155.
96. Honig LS, Kukull W, Mayeux R Atherosclerosis and AD: Analysis of data from the U.S. National Alzheimer's Coordinating Center. Neurology 2005, 64:494-500.
97. Korczyn AD Mixed dementia-The most common form of dementia. Ann N Y Acad Sci 2002, 977:129-134.
98. Nicoll JA, Yamada M, Frackowiac J, Mazur-Kolecka B, Weller RO Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. Neurobiol Aging 2004, 25:589-597.
99. Rasquin SM, Lodder J, Verhey FR The effect of different diagnostic criteria on the prevalence and incidence of post-stroke dementia. Neuroepidemiology 2005, 24:189-195.
100. Bowen J, Teri L, Kukull W, et al. Progression to dementia in patients with isolated memory loss. Lancet 1997, 349:763-765.
101. Kivipelto M, Helkala EL, Hanninen T, et al. Midlife vascular risk factors and late-life mild cognitive impairment. A population-based study. Neurology 2001, 56:1683-1689.
102. DeCarli C, Miller BL, Swan GE, et al. Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol 2001, 58:643-647.
103. Abbott RD, White LR, Ross GW, et al. Walking and dementia in physically capable elderly men. JAMA 2004, 292:1447-1453.
104. Newman AB, Fitzpatrick AL, Lopez O, et al. Dementia and Alzheimer's disease in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc 2005, 53:1101-1107.
105. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology 1993, 43:250-260.
106. Wetterling T, Kanitz RD, Borgis KJ Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke 1996, 27:30-36.
107. Chui HC, Mack W, Jackson JE, et al. Clinical criteria for the diagnosis of vascular dementia: A multicenter study of comparability and interrater reliability. Arch Neurol 2000, 57:191-196.
108. Sachdev PS, Brodaty H, Valenzuela MJ, et al. The neuropsychological profile of vascular cognitive impairment in stroke and TIA patients. Neurology 2004, 62:912-919.
109. Graham NL, Emery T, Hodges JR Distinctive cognitive profiles in Alzheimer's disease and subcortical vascular dementia. J Neurol Neurosurg Psychiatr 2004, 75:61-71.
110. Reed BR, Mungas DM, Kramer JH, et al. Clinical and neuropsychological features in autopsy-defined vascular dementia. Clin Neuropsychol 2004, 18:63-74.
111. Kish SJ, El-Awar M, Schut L, et al. Cognitive deficits in olivopontocerebellar atrophy: Implications for the cholinergic hypothesis of Alzheimer's dementia. Ann Neurol 1988, 24:200-206.
112. Robbins T, James M, Owen A, et al. Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. J Neurol Neurosurg Psychiatr 1994, 57:79-88.
113. Berciano J Olivopontocerebellar atrophy: A review of 117 cases. J Neurol Sci 1982, 53:253-272.
114. Berent S, Giordant B, Gilman S, et al. Neuropsychological changes in olivopontocerebellar atrophy. Arch Neurol 1990, 47:997-1001.
115. Mann D, Oliver R, Snowden J The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy. Acta Neuropathol 1993, 85:553-559.
116. Heinsen H, Strik M, Bauer M, et al. Cortical and striatal neurone number in Huntington's disease. Acta Neuropathol 1994, 88:320-333.
117. Jackson M, Gentleman S, Lennox G, et al. The cortical neuritic pathology of Huntington's disease. Neuropathol Appl Neurobiol 1995, 21:18-26.
118. Storey E, Kowall N, Finn S, et al. The cortical lesion of Huntington's disease: Further neurochemical characterization, and reproduction of some of the histological and neurochemical features by N-methyl- d-aspartate lesion of rat cortex. Ann Neurol 1992, 32:526-534.
119. Mazziotta JC, Phelps ME, Pahl JJ, et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med 1987, 316:357-362.
120. Bamford KA, Caine ED, Kido DK, et al. Clinical-pathologic correlation in Huntington's disease: A neuropsychological and computed tomography study. Neurology 1989, 39:796-801.
121. Berent S, Giordani B, Markel D, et al. Positron emission tomographic scan investigations of Huntington's disease: Cerebral metabolic correlates of cognitive function. Ann Neurol 1988, 23:541-546.
122. Bamford KA, Caine ED, Kido DK, et al. A prospective evaluation of cognitive decline in early Huntington's disease: Functional and radiographic correlates. Neurology 1995, 45:1867-1873.
123. Massman PJ, Delis DC, Butters N, et al. Are all subcortical dementias alike? Verbal learning and memory in Parkinson's and Huntington's disease patients. J Clin Exp Neuropsychol 1990, 12:729-744.
124. Mesulam M Primary progressive aphasia without generalized dementia. Ann Neurol 1982, 11:592-598.
125. Snowden JS, Neary D, Mann DMA, et al. Progressive language disorder due to lobar atrophy. Ann Neurol 1992, 31:174-183.
126. Lippa CF, Cohen R, Smith TW, Drachman DA Primary progressive aphasia with focal neuronal achromasia. Neurology 1991, 41:882-886.
127. Morris JC, Cole M, Banker BQ, Wright D Hereditary dysphasic dementia and the Pick-Alzheimer spectrum. Ann Neurol 1984, 16:455-466.
128. Graff-Radford NR, Damasio AR, Hyman BT, et al. Progressive aphasia in a patient with Pick's disease: A neuropsychologic, radiologic, and anatomic study. Neurology 1990, 40:620-626.
129. Kirshner HS, Tanridag O, Thurman L, Whetsell WO Progressive aphasia without dementia: Two cases with focal spongiform degeneration. Ann Neurol 1987, 22:527-532.
130. Benson D, Zaias B Progressive aphasia: A case with postmortem correlation. Neuropsychiatr Neuropsychol Behav Neurol 1991, 4:215-223.
131. Tissot R, Constantinidis J, Richard J Pick's disease. Handbook of Clinical Neurology 1985, Vol 46:233-246. Elsevier, Amsterdam.
132. Mizukami K, Kosaka K Neuropathological study on the nucleus basalis of Meynert in Pick's disease. Acta Neuropathol 1989, 78:52-56.
133. Lang A, Bergeron C, Pollanen M, Ashby P Parietal Pick's disease mimicking cortical-basal ganglionic degeneration. Neurology 1994, 44:1436-1440.
134. Ghetti B, Murrell JR, Zolo P, Spillantini MG, Goedert M Progress in hereditary tauopathies: A mutation in the Tau gene (G389R) causes a Pick disease-like syndrome. Ann N Y Acad Sci 2000, 920:52-62.
135. Pringle CE, Hudson AJ, Munoz DG, et al. Primary lateral sclerosis: Clinical features, neuropathology, and diagnostic criteria. Brain 1992, 115:495-520.
136. Tang-Wai D, Graff-Radford N, Boeve B, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004, 63:1168-1174.
137. Saito Y, Yamazaki M, Kanazawa I, Murayama S Severe involvement of the ambient gyrus in a case of dementia with argyrophilic grain disease. J Neurol Sci 2002, 196:71-75.
138. Jagust W, Davies P, Tiller-Borcich J, Reed B Focal Alzheimer's disease. Neurology 1990, 40:14-19.
139. Scully R, Mark E, McNeely W, McNeely B Case records of the Massachusetts General Hospital (Case 46-1993). N Engl J Med 1993, 329:1560-1567.
140. Riley DE, Lang AE, Lewis A, et al. Cortical-basal ganglionic degeneration. Neurology 1990, 40:1203-1212.
141. Reed LA, Wszolek ZK, Hutton M Phenotypic correlations in FTDP-17. Neurobiol Aging 2001, 22(1):89-107.
142. Caselli RJ, Reiman EM, Timmann D, et al. Progressive apraxia in clinically discordant monozygotic twins. Arch Neurol 1995, 52:1004-1010.
143. Caselli RJ, Windebank AJ, Petersen RC, et al. Rapidly progressive aphasic dementia and motor neuron disease. Ann Neurol 1993, 33:200-207.
144. Neary D, Snowden J, Mann D, et al. Frontal lobe dementia and motor neuron disease. J Neurol Neurosurg Psychiatr 1990, 53:23-32.
145. Dickson DW, Horoupian DS, Thal LJ, et al. Kluver-Bucy syndrome and amyotrophic lateral sclerosis: A case report with biochemistry, morphometrics, and Golgi study. Neurology 1986, 36:1323-1329.
146. Pick A On the relation between aphasia and senile atrophy of the brain. Translated by WC Schoene from Pick A: Über die Beziehungen der senilen Hirnatrophie zur Aphasie. Prager Medicinische Wochenschrift 1977, 17(16):35-40. Hafner, New York. D.A. Rottenberg, F.H. Hochberg (Eds.).
147. Tyrrell PJ, Warrington EK, Frackowiak RSJ, Rossor MN Progressive degeneration of the right temporal lobe studied with positron emission tomography. J Neurol Neurosurg Psychiatr 1990, 53:1046-1050.
148. Boeve B, Lang A, Litvan I Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003, 54:S15-S19.
149. Brun A Frontal lobe degeneration of non-Alzheimer type: 1. Neuropathology. Arch Gerontol Geriatr 1987, 6:193-208.
150. Gustafson L Frontal lobe degeneration of non-Alzheimer type: II. Clinical picture and differential diagnosis. Arch Gerontol Geriatr 1987, 6:209-223.
151. Caselli RJ, Smith BE, Osborne D Primary lateral sclerosis: A neuropsychological study. Neurology 1995, 45:2005-2009.
152. Hudson A Amyotrophic lateral sclerosis and its association with dementia, parkinsonism and other neurologic disorders: A review. Brain 1981, 104:217-247.
153. Horoupian D, Thal L, Katzman R, et al. Dementia and motor neuron disease: Morphometric, biochemical, and Golgi studies. Ann Neurol 1984, 16:305-313.
154. Hirano A, Kurland LT, Krooth RS, Lessell S Parkinsonism-dementia complex, an endemic disease on the island of Guam: I. Clinical features. Brain 1961, 84:642-661.
155. Lomen-Hoerth C, Anderson T, Miller B The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002, 59:1077-1079.
156. Mott RT, Dickson DW, Trojanowski JQ, et al. Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias. J Neuropathol Exp Neurol 2005, 64:420-428.
157. Litvan I Cognitive disturbances in progressive supranuclear palsy. J Neural Transm 1994, 42(Suppl):69-78.
158. Pillon B, Dubois B, Ploska A, Agid Y Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsy. Neurology 1991, 41:634-643.
159. D'Antona R, Baron J, Samson Y, et al. Subcortical dementia: Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. Brain 1985, 108:785-799.
160. Verny M, Duyckaerts C, Delaere P, et al. Cortical tangles in progressive supranuclear palsy. J Neural Transm 1994, 42:179-188.
161. Golbe LI The epidemiology of PSP. J Neural Transm 1994, 42:263-273.
162. Rippon G, Boeve B, Parisi J, et al. Late-onset frontotemporal dementia associated with progressive supranuclear palsy/argyrophilic grain disease/Alzheimer's disease pathology. Neurocase 2005, 11:204-211.
163. Josephs K, Boeve B, Duffy J, et al. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. Neurocase 2005, 11:283-296.
164. Gibb W, Luthert P, Marsden CD Corticobasal degeneration. Brain 1989, 112:1171-1192.
165. Feany M, Dickson D Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am J Pathol 1995, 146:1388-1396.
166. Rebeiz JJ, Kolodny EH, Richardson EP Corticodentatonigral degeneration with neuronal achromasia: A progressive disorder of late adult life. Trans Am Neurol Assoc 1967, 92:23-26.
167. Lang AE, Maragonore D, Marsden CD, Tanner C Movement Disorder Society Symposium on Cortical-Basal Ganglionic Degeneration (CBD) and Its Relationship to Other Asymmetric Cortical Degeneration Syndromes (ACDs). Mov Disord 1996, 11:346-357.
168. Kompoliti K, Goetz CG, Boeve BF, et al. Clinical presentation and pharmacologic therapy in corticobasal degeneration. Arch Neurol 1998, 55:957-963.
169. Beach TG, Sue L, Scott S, et al. Hippocampal sclerosis dementia with tauopathy. Brain Pathol 2003, 13:263-278.
170. Peskind ER, Nochlin D, Raskind MA Clinical and neuropathological characteristics of hippocampal sclerosis: A community-based study. Arch Neurol 2002, 59:1099-1106.
171. Continuum, Issue on Dementia February 2004, American Academy of Neurology, St. Paul, MN.
172. Dubinsky RM, Stein AC, Lyons K Risk of driving and Alzheimer's disease (an evidence based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 54:2205-2211.
173. Forman MS, Farmer J, Johnson JK, et al. Frontotemporal dementia: Clinicopathological correlations. Ann Neurol 2006, 59:952-962.
174. Galvin JE, Pollack J, Morris JC Clinical phenotype of Parkinson's disease dementia. Neurology 2006, 67:1605-1611.
175. Heindel WC, Salmon DP, Shults CW, et al. Neuropsychological evidence for multiple memory systems: A comparison of Alzheimer's, Huntington's, and Parkinson's disease patients. J Neurosci 1989, 9:582-587.
176. Honig LS, Kukull W, Mayeux R Atherosclerosis and AD: Analysis of data from the U.S. National Alzheimer's Coordinating Center. Neurology 2005, 64:494-500.
177. Huey ED, Putnam KT, Grafman J A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006, 66:17-22.
178. Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 2006, 63:674-681.
179. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1143-1153.
180. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996, 47:1113-1124.
181. McKeith IG Clinical Lewy body syndromes. Ann N Y Acad Sci 2000, 920:1-8.
182. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
183. Morris JC The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 1993, 43:2412-2414.
184. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early stage Alzheimer disease. Arch Neurol 2001, 58:397-405.
185. Mott RT, Dickson DW, Trojanowski JQ, et al. Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias. J Neuropathol Exp Neurol 2005, 64:420-428.
186. Peterson RC, Paris JE, Dickson DW, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006, 63:665-672.
187. Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Neurology 2001, 56:1133-1142.
188. Scarmeas N, Stern Y, Tang M-X, Mayeux R, Luchsinger JA Mediterranean diet and risk for Alzheimer's disease. Ann Neurol 2006, 59:912-921.
189. Sink KM, Holden KF, Yaffe K Pharmacological treatment of neuropsychiatric symptoms of dementia. JAMA 2005, 293:596-608.
190. Smith GE, Kokmen E, O'Brien PC Risk factors for nursing home placement in a population-based dementia cohort. J Am Geriatr Soc 2000, 48:519-525.
191. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment-Beyond controversies towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004, 256:240-246.
192. Interactive study questions and referenced videos forthis chapter are available on the DVD-ROM.